Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 amp |
| Therapy | Cisplatin + Etoposide + GSK3052230 |
| Indication/Tumor Type | lung small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 amp | lung small cell carcinoma | sensitive | Cisplatin + Etoposide + GSK3052230 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011). | 23536011 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (23536011) | Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. | Full reference... |